Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Protein and Peptide Science
  4. Fast Track Articles
  5. Fast Track Article
image of Circulating SFRP2 in Iranian Polycystic Ovarian Syndrome Patients with Infertility and Recurrent Pregnancy Loss and its Correlation with Insulin Resistance and Inflammation

Abstract

Introduction

Secreted Frizzled-Related Protein 2 (SFRP2) is considered to be the most potent modulator of the Wnt signaling. This pathway is involved in the pathogenesis of Polycystic Ovary Syndrome (PCOS). This research aimed to compare the levels of SFRP2 in PCOS [infertile and Recurrent Pregnancy Loss (RPL) patients] with the control group and determine the correlation of SFRP2 with inflammation and insulin resistance.

Methods

This case-control study was conducted on 108 POCS patients (53 infertile patients and 55 women with RPL) and 54 healthy controls. The levels of biochemical factors along with SFRP2, adiponectin, Luteinizing Hormone (LH), Follicle-Stimulating Hormone (FSH), free testosterone, and insulin, high-sensitivity C-Reactive Protein (hs-CRP) were measured following the manufacturer's instructions.

Results

Both infertile and RPL groups presented notably higher levels of SFRP2 (49.32 ± 17.72 ng/ml and 55.89 ± 17.36 ng/ml, respectively) compared to the control group (30.21 ± 10.12 ng/ml, 0.001 for both groups). In PCOS patients, a positive correlation was observed between SFRP2 and body mass index (BMI) (r = 0.42, 0.001), insulin (r = 0.19, P = 0.04), fasting blood glucose (FBG) (r = 0.24, P = 0.01), Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) (r = 0.21, P = 0.03), triglyceride (r = 0.25, P = 0.009), and hs-CRP (r = 0.21, P = 0.02). Furthermore, SFRP2 increased the risk of RPL (OR [95% CI] = 1.15 [1.10 -1.20], 0.001) and infertility (OR [95% CI] = 1.12 [1.07 -1.17], 0.001) in comparison with the controls.

Conclusion

Our findings suggested that SFRP2 may have a potential involvement in the development of PCOS and might be a promising target for diagnosis, but additional research is required to confirm this.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpps/10.2174/0113892037339007250120100322
2025-02-12
2025-05-16

  • From This Site

    /content/journals/cpps/10.2174/0113892037339007250120100322
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Bicer M. Alarslan P. Guler A. Demir I. Aslanipour B. Calan M. Elevated circulating levels of secreted frizzled-related protein 4 in relation to insulin resistance and androgens in women with polycystic ovary syndrome. J. Endocrinol. Invest. 2020 43 3 305 313 10.1007/s40618‑019‑01108‑4 31486991
    [Google Scholar]
  2. Jabeen A. Yamini V. Rahman Amberina A. Dinesh Eshwar M. Vadakedath S. Begum G.S. Kandi V. Polycystic ovarian syndrome: Prevalence, predisposing factors, and awareness among adolescent and young girls of South India. Cureus 2022 14 8 e27943 10.7759/cureus.27943 36120281
    [Google Scholar]
  3. Escobar-Morreale HF Luque-Ramírez M González F Circulating inflammatory markers in polycystic ovary syndrome: A systematic review and metaanalysis. Fertil. Steril. 2011 95 3 1048 1058 10.1016/j.fertnstert.2010.11.036
    [Google Scholar]
  4. İnal H.A. Yilmaz N. Gorkem U. Oruc A.S. Timur H. The impact of follicular fluid adiponectin and ghrelin levels based on BMI on IVF outcomes in PCOS. J. Endocrinol. Invest. 2016 39 4 431 437 10.1007/s40618‑015‑0392‑6 26410834
    [Google Scholar]
  5. Barber T. Franks S. Genetic and environmental factors in the etiology of polycystic ovary syndrome. The Ovary. Elsevier 2019 437 459 10.1016/B978‑0‑12‑813209‑8.00027‑3
    [Google Scholar]
  6. Xu Y. Qiao J. Association of insulin resistance and elevated androgen levels with polycystic ovarian syndrome (PCOS): A review of literature. J. Healthc. Eng. 2022 2022 1 1 13 10.1155/2022/9240569 35356614
    [Google Scholar]
  7. Vatannejad A. Fadaei R. Salimi F. Fouani F.Z. Habibi B. Shapourizadeh S. Eivazi S. Eivazi S. Sadeghi A. Moradi N. Plasma Complement C1q/tumor necrosis factor-related protein 15 concentration is associated with polycystic ovary syndrome. PLoS One 2022 17 6 e0263658 10.1371/journal.pone.0263658 35700181
    [Google Scholar]
  8. Kamalanathan S. Sahoo J. Sathyapalan T. Pregnancy in polycystic ovary syndrome. Indian J. Endocrinol. Metab. 2013 17 1 37 43 10.4103/2230‑8210.107830 23776851
    [Google Scholar]
  9. Wartena R. Matjila M. Polycystic ovary syndrome and recurrent pregnancy loss, a review of literature. Front. Endocrinol. 2023 14 1183060 10.3389/fendo.2023.1183060 38027110
    [Google Scholar]
  10. Cena H. Chiovato L. Nappi R.E. Obesity, polycystic ovary syndrome, and infertility: A new avenue for GLP-1 receptor agonists. J. Clin. Endocrinol. Metab. 2020 105 8 e2695 e2709 10.1210/clinem/dgaa285 32442310
    [Google Scholar]
  11. Dimitriadis G. Kyrou I. Randeva H. Polycystic ovary syndrome as a proinflammatory state: The role of adipokines. Curr. Pharm. Des. 2016 22 36 5535 5546 10.2174/1381612822666160726103133 27464726
    [Google Scholar]
  12. Inal Z.O. Inal H.A. Erdem S. The effect of serum and follicular fluid secreted frizzle-related protein-5 on in vitro fertilization outcomes in patients with polycystic ovary syndrome. Mol. Biol. Rep. 2018 45 6 2037 2044 10.1007/s11033‑018‑4360‑z 30194556
    [Google Scholar]
  13. Wang Y. Zhu W. Evaluation of adiponectin, resistin, IL-6, TNF-α in obese and non-obese women with polycystic ovary syndrome. Reprod. Contracept. 2012 23 4 237 244 10.1016/S1001‑7844(12)60032‑7
    [Google Scholar]
  14. Maman E. Yung Y. Cohen B. Konopnicki S. Dal Canto M. Fadini R. Kanety H. Kedem A. Dor J. Hourvitz A. Expression and regulation of sFRP family members in human granulosa cells. Mol. Hum. Reprod. 2011 17 7 399 404 10.1093/molehr/gar010 21307090
    [Google Scholar]
  15. Alhilfi A.S.N. Afrisham R. Sefidan A.M. Fadaei R. Moradi N. Saed L. Einollahi N. A positive correlation of serum SFRP1 levels with the risk of developing type 2 diabetes mellitus: A case-control study. Lab. Med. 2024 55 6 739 744 10.1093/labmed/lmae030 38801722
    [Google Scholar]
  16. Zhang Y. Ran Y. Kong L. Geng L. Huang H. Zhang H. Hu J. Qi H. Chen Y. Decreased SFRP5 correlated with excessive metabolic inflammation in polycystic ovary syndrome could be reversed by metformin: implication of its role in dysregulated metabolism. J. Ovarian Res. 2021 14 1 97 10.1186/s13048‑021‑00847‑4 34284806
    [Google Scholar]
  17. Crowley R.K. O’Reilly M.W. Bujalska I.J. Hassan-Smith Z.K. Hazlehurst J.M. Foucault D.R. Stewart P.M. Tomlinson J.W. SFRP2 is associated with increased adiposity and VEGF expression. PLoS One 2016 11 9 e0163777 10.1371/journal.pone.0163777 27685706
    [Google Scholar]
  18. Ajmal N. Khan S.Z. Shaikh R. Polycystic ovary syndrome (PCOS) and genetic predisposition: A review article. Eur. J. Obstet. Gynecol. Reprod. Biol. X 2019 3 100060 10.1016/j.eurox.2019.100060 31403134
    [Google Scholar]
  19. Cao M. Wang H. Li W. Jiang X. Wang X. Guo W. Gao P. Zou Y. Inverse associations between circulating secreted frizzled related protein 2 (sFRP2) and cardiometabolic risk factors. Front. Cardiovasc. Med. 2021 8 723205 10.3389/fcvm.2021.723205 34722660
    [Google Scholar]
  20. Kumar Shrewastwa M. Acharya V. Kumar Mahat A. Association of secreted frizzled-related protein 4 with obesity and type II diabetes. Nepal Med. J. 2023 5 2 50 56 10.37080/nmj.148
    [Google Scholar]
  21. Beernink R.H. Schuitemaker J.H. Secreted Frizzled-Related Proteins 4 and 5: What They Are and Can They Be Used as a Biomarker in Gestational Diabetes Mellitus. Biomarkers in Diabetes. Springer 2022 629 648
    [Google Scholar]
  22. Zhou M. Jiao L. Liu Y. sFRP2 promotes airway inflammation and Th17/Treg imbalance in COPD via Wnt/β-catenin pathway. Respir. Physiol. Neurobiol. 2019 270 103282 10.1016/j.resp.2019.103282 31430541
    [Google Scholar]
  23. Bujalska I. Rabbitt E. Stewart P. Effect of secreted frizzled-related protein 2 (sFRP2) from adipose tissue on pancreatic cell function. Endocrine Abstracts. Bioscientifica 2012
    [Google Scholar]
  24. Cercato C. Fonseca F.A. Cardiovascular risk and obesity. Diabetol. Metab. Syndr. 2019 11 1 74 10.1186/s13098‑019‑0468‑0 31467596
    [Google Scholar]
  25. Ehrlund A. Mejhert N. Lorente-Cebrián S. Åström G. Dahlman I. Laurencikiene J. Rydén M. Characterization of the Wnt inhibitors secreted frizzled-related proteins (SFRPs) in human adipose tissue. J. Clin. Endocrinol. Metab. 2013 98 3 E503 E508 10.1210/jc.2012‑3416 23393180
    [Google Scholar]
  26. Mastri M. Shah Z. Hsieh K. Wang X. Wooldridge B. Martin S. Suzuki G. Lee T. Secreted Frizzled-related protein 2 as a target in antifibrotic therapeutic intervention. Am. J. Physiol. Cell Physiol. 2014 306 6 C531 C539 10.1152/ajpcell.00238.2013 24336656
    [Google Scholar]
/content/journals/cpps/10.2174/0113892037339007250120100322
Loading
Circulating SFRP2 in Iranian Polycystic Ovarian Syndrome Patients with Infertility and Recurrent Pregnancy Loss and its Correlation with Insulin Resistance and Inflammation
Bentham Science Publishers ; https://doi.org/10.2174/0113892037339007250120100322
/content/journals/cpps/10.2174/0113892037339007250120100322
/content/journals/cpps/10.2174/0113892037339007250120100322
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: and recurrent pregnancy loss ; insulin resistance ; infertility ; polycystic ovary syndrome ; Secreted frizzled-related protein 2 ; inflammation

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test